PM012

VTBIO Co. LTD · Phase 2 active Small molecule

At a glance

Generic name	PM012
Also known as	650-mg PM012 tablet
Sponsor	VTBIO Co. LTD
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease (PHASE2, PHASE3)
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PM012 CI brief — competitive landscape report
PM012 updates RSS · CI watch RSS
VTBIO Co. LTD portfolio CI